Jaundice is a critical global health issue among newborns

Jaundice is the #1 reason why newborns are readmitted to hospitals worldwide. About 3 in 5 children have some degree of jaundice. For approximately 16.5% of babies, the condition is severe and requires treatment. Severe jaundice, when left untreated or ineffectively treated, can lead to severe brain damage, a condition called kernicterus, or death.

Millions of babies are not receiving the effective care they need

With experts at Stanford University School of Medicine, we estimate that every year, over 6 million babies with severe jaundice are not receiving adequate treatment.

Every year, over
6 million babies
with severe jaundice are not receiving adequate treatment

Yet, jaundice is easy to treat.
If detected early enough, it simply
requires shining intense blue light
onto a baby’s skin

Current treatment devices are costly to purchase and maintain

In studies of medical facilities in India and Nigeria, D-Rev and Stanford found that 95% of devices evaluated in low-income hospitals and clinics did not meet American Academy of Pediatrics standards for intensive phototherapy. Maintenance was a key limitation in delivery of treatment: approximately 1 in 3 phototherapy devices had at least one bulb burned out or missing. Compact florescent bulbs, commonly used in phototherapy devices, cost approximately $15 per bulb to replace and last approximately four months. Many hospitals have trouble sourcing these bulbs and, with devices using an average of six bulbs each, they simply can’t afford to replace them as needed.


Of devices in low-income hospitals and clinics did not meet American Academy of Pediatrics standards

1 in 3 devices had at least one bulb burnt out or missing

We are starting where the need is most critical

We learned from our fieldwork and due diligence that urban and district hospitals rarely have effective phototherapy—in fact only 5% in our target areas. To reach the most newborns, Brilliance targets hospitals where the sickest children are referred.

The Design

World-Class Treatment

Tests at Stanford School of Medicine show Brilliance to perform on par or better than state-of-the-art phototherapy devices.

Minimal Maintenance

Brilliance LEDs last over 60x longer than compact fluorescent lamps (CFL) commonly used in phototherapy devices. With Brilliance, hospitals can save over $600 USD per year by avoiding costly bulb replacements.


Brilliance received CE mark in October 2013, certifying that the product meets European Union standards for safety and quality.

D-Rev Brilliance

Energy Efficient

Brilliance consumes less than half the power of compact fluorescent tube lights which enables Brilliance to run off of a hospital’s back-up energy (for example a solar panel size…) to efficiently share energy with other machines. A typical CFL device will rack up energy costs of $39 per unit per year, while each Brilliance unit uses only $19 of energy per year.

Adjustable & Easy to Use

D-Rev is user-obsessed. We’ve talked to medical staff in over 200 hospitals and clinics around the world. Brilliance is designed for versatility of use and it meets American Academy of Pediatrics recommendations for interactions with other critical medical equipment such as infant warmers, incubators, and a variety of bassinets.

D-Rev research and collaborations

The Need to Implement Effective Phototherapy in Resource-Constrained Settings

Device Effectiveness in Nigeria: Current Irradiance Levels and Simple Strategies for Improvement

A Global Strategy to Screen and Prevent the Need for the Exchange Transfusion

The Delivery

In late 2010, D-Rev licensed Brilliance to Phoenix Medical Systems in Chennai, India. Phoenix is the largest manufacturer and seller of quality neonatal care equipment in India with 70% of the market share of compact florescent bulb phototherapy devices in the country. Brilliance was released on the market in November 2012. Phoenix is currently manufacturing, distributing, and selling Brilliance throughout India and much of the rest of the world.

About The Deal

About The Deal

The licensing agreement is structured to incentivize sales to public hospitals in India and low-income countries. Specifically, the target markets are countries categorized by the United Nations Human Development Index as low or medium resource-limited. Through dialogue with Indian medical professionals, D-Rev and Phoenix have agreed to cap the selling price of Brilliance at 400 USD (22,000 INR) based on the cost of goods sold to ensure affordability in emerging and undercapitalized markets.

About Phoenix

Established in 1989, Phoenix is committed to quality, technology, and innovation with an excellent in-house research and development team. Phoenix products are trusted worldwide and used in almost all premier hospital and medical institutions in India. Phoenix has ISO certifications and pursues international standards in ensuring the highest safety of all its products.

Brilliance is on the market and can be ordered directly through our partner, Phoenix Medical Systems

Order Brilliance

Order Brilliance

The Impact

Impact 31,749

babies treated with Brilliance

Impact 26,630

babies treated who would not otherwise have received effective treatment

Impact 629

newborn deaths and disabilities averted

Impact 657

units installed

View Full Dashboard